Clinical Trial Update: A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating Fluzoparib (SHR-3162) with temozolomide, with or without SHR-1316, in relapsed small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Fluzoparib (fluzoparib)
• SHR-1316
• Temozolomide (Temozolomide)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED